menu search

BLCO / Bausch + Lomb prices IPO at $18 a share, below expectations

Bausch + Lomb prices IPO at $18 a share, below expectations
Bausch + Lomb Corp. priced its IPO at $18 a share Thursday, falling short of expectations as it became the first big company in months to try going public into a turbulent stock market. Read More
Posted: May 6 2022, 00:10
Author Name: Fox Business
Views: 111533

BLCO News  

Bausch + Lomb Corporation (BLCO) Q3 2023 Earnings Call Transcript

By Seeking Alpha
November 1, 2023

Bausch + Lomb Corporation (BLCO) Q3 2023 Earnings Call Transcript

Bausch + Lomb Corporation (NYSE:BLCO ) Q3 2023 Earnings Conference Call November 1, 2023 8:00 AM ET Company Participants George Gadkowski - Vice Presi more_horizontal

Is the Options Market Predicting a Spike in Bausch + Lomb (BLCO) Stock?

By Zacks Investment Research
September 19, 2023

Is the Options Market Predicting a Spike in Bausch + Lomb (BLCO) Stock?

Investors need to pay close attention to Bausch + Lomb (BLCO) stock based on the movements in the options market lately. more_horizontal

Bausch + Lomb (BLCO) Beats Q2 Earnings and Revenue Estimates

By Zacks Investment Research
August 2, 2023

Bausch + Lomb (BLCO) Beats Q2 Earnings and Revenue Estimates

Bausch + Lomb (BLCO) came out with quarterly earnings of $0.18 per share, beating the Zacks Consensus Estimate of $0.16 per share. This compares to ea more_horizontal

BLCO or DOCS: Which Is the Better Value Stock Right Now?

By Zacks Investment Research
July 6, 2023

BLCO or DOCS: Which Is the Better Value Stock Right Now?

Investors interested in Medical Services stocks are likely familiar with Bausch + Lomb (BLCO) and Doximity (DOCS). But which of these two stocks is mo more_horizontal

Bausch + Lomb (BLCO) Q1 Earnings Lag Estimates

By Zacks Investment Research
May 3, 2023

Bausch + Lomb (BLCO) Q1 Earnings Lag Estimates

Bausch + Lomb (BLCO) came out with quarterly earnings of $0.10 per share, missing the Zacks Consensus Estimate of $0.14 per share. This compares to ea more_horizontal

Bausch + Lomb: Brent Saunders Return Bodes Well For Shareholders

By Seeking Alpha
February 27, 2023

Bausch + Lomb: Brent Saunders Return Bodes Well For Shareholders

Brent Saunders led Bausch + Lomb Corporation when it was sold to Valeant Pharmaceuticals. He later led and sold competitor Allergan to AbbVie. more_horizontal

Bausch + Lomb Corporation (BLCO) Q4 2022 Earnings Call Transcript

By Seeking Alpha
February 22, 2023

Bausch + Lomb Corporation (BLCO) Q4 2022 Earnings Call Transcript

Bausch + Lomb Corporation (NYSE:BLCO ) Q4 2022 Earnings Conference Call February 22, 2023 8:00 AM ET Company Participants Art Shannon – Investor Rel more_horizontal

Bausch + Lomb beats Q4 profit and revenue estimates

By Market Watch
February 22, 2023

Bausch + Lomb beats Q4 profit and revenue estimates

Bausch + Lomb Corp. BLCO, -2.01% said Wednesday it had a loss of $1 million, or breakeven on a per-share basis, for the fourth quarter, after earnings more_horizontal


Search within

Pages Search Results: